Defactinib Posters

Phase I Study of Defactinib Combined with Pembrolizumab and Gemcitabine in Advanced Cancer

Andrea Wang-Gillam, A. Craig Lockhart, Benjamin Tan, Rama Suresh, Kian-Huat Lim, Lee Ratner, Ashely Morton, Jess Huffman, Samantha Marquez, Nicolas Boice, David G DeNardo
Presented at the 2018 American Society for Clinical Oncology Annual Meeting | Chicago, Illinois, USA | June 1-5, 2018

An Alternative Splicing Signature that Identifies Breast Cancer Stem Cells

Irina M. Shapiro, Jiangwen Zhang, Alan G. Derr, Christian M. Vidal, Alissa A. Neill, Qunli Xu, Daniel W. Paterson, Jonathan A. Pachter and David T. Weaver
April 02, 2012
LB-197; American Association for Cancer Research Annual Meeting

The Wnt Inhibitor VS-507 Reduces Cancer Stem Cell Function in vitro and Tumorigenicity in Mice

Jonathan A. Pachter, Jennifer E. Ring, Vihren N. Kolev, Alissa A. Neill, Christian M. Vidal, Brian T. Sullivan, Kevin T. Sprott, Mahesh V. Padval and Qunli Xu
April 02, 2012
LB-194; American Association for Cancer Research Annual Meeting

The FAK Inhibitors VS-4718 and VS-5095 Attenuate Breast Cancer Stem Cell Function in vitro and Tumor Growth in vivo

Qunli Xu, Christian M. Vidal, Jennifer E. Ring, Vihren N. Kolev, Irina M. Shapiro, Alissa A. Neill, Kevin T. Sprott, Mitchell Keegan, Daniel W. Paterson, Mahesh V. Padval and Jonathan A. Pachter.
April 02, 2012
LB-192; American Association for Cancer Research Annual Meeting

Gene Expression and Alternative Splicing Signatures Discriminate Breast Cancer Stem Cells from Fibroblasts

David T. Weaver, Irina M. Shapiro, Alan G. Derr, Daniel W. Paterson, Jonathan A. Pachter
June 04, 2012
1057; American Society of Clinical Oncology

Defactinib Presentations

iMig 2014: Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM

Raphael Bueno1, Ritu R Gill1, Julianne Barlow1, David M Jackman1, Beow Y Yeap1, David Weaver2, Mahesh Padval2, Rachel Sorensen2, Mitchell Keegan2
October 23, 2014
iMig, Cape Town October 2014

  1. Brigham and Women’s Hospital, Boston, MA, USA; 2. Verastem, Inc., Boston, MA, USA
iMig 2014: FAK Inhibitor VS-6063 (defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy

Paul Baas, Department of Thorax Oncology Netherlands Cancer Institute, Amsterdam
October 23, 2014
iMig, Cape Town October 2014

WCLC 2015: The Cancer Stem Cell Inhibitors VS-6063 and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma

Mitchell Keegan
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Development, Verastem, Inc.